Oncopeptides AB (publ) (FRA:OND)

Oncopeptides AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	71.12	31.65	35.22	8.36	118.3
Revenue Growth (YoY)	124.72%	-10.14%	321.54%	-92.94%	-
Cost of Revenue	2.45	2.66	-1.08	0.01	53.12
Gross Profit	68.67	28.99	36.3	8.35	65.17
Selling, General & Admin	194.62	197.28	188.48	142.2	873.81
Research & Development	102.97	121.19	106.95	217.66	679.93
Other Operating Expenses	-4.27	-6.9	-6.34	-4.57	3.9
Operating Expenses	293.32	311.57	289.09	355.29	1,558
Operating Income	-224.65	-282.59	-252.79	-346.94	-1,492
Interest Expense	-23.52	-12.66	-5.79	-0.88	-0.95
Interest & Investment Income	-	8.2	8.59	2.62	0.49
Currency Exchange Gain (Loss)	-	2.84	1.54	8.96	71.54
Other Non Operating Income (Expenses)	-	0	-	-	0
EBT Excluding Unusual Items	-248.17	-284.21	-248.45	-336.24	-1,421
Gain (Loss) on Sale of Assets	-	-	-	-1.44	-
Pretax Income	-248.17	-284.21	-248.45	-337.68	-1,421
Income Tax Expense	1.42	0.4	0.66	0.27	8.95
Net Income	-249.59	-284.61	-249.11	-337.95	-1,430
Net Income to Common	-249.59	-284.61	-249.11	-337.95	-1,430
Shares Outstanding (Basic)	998	166	90	82	75
Shares Outstanding (Diluted)	998	166	90	82	75
Shares Change (YoY)	499.81%	84.14%	9.80%	9.33%	20.72%
EPS (Basic)	-0.25	-1.71	-2.76	-4.11	-19.00
EPS (Diluted)	-0.25	-1.71	-2.76	-4.11	-19.00
Free Cash Flow	-216.49	-260.93	-279.61	-423.02	-1,517
Free Cash Flow Per Share	-0.22	-1.57	-3.09	-5.14	-20.14
Gross Margin	96.55%	91.59%	103.06%	99.93%	55.09%
Operating Margin	-315.88%	-892.91%	-717.74%	-4152.44%	-1261.64%
Profit Margin	-350.94%	-899.29%	-707.30%	-4044.90%	-1209.11%
Free Cash Flow Margin	-304.41%	-824.47%	-793.89%	-5063.03%	-1282.16%
EBITDA	-222.18	-280.12	-250.35	-344.93	-1,491
D&A For EBITDA	2.47	2.47	2.44	2.01	1.72
EBIT	-224.65	-282.59	-252.79	-346.94	-1,492

Source: S&P Global Market Intelligence. Standard template. Financial Sources.